Its amplification or overexpression was initially associated with poor survival rates in breast cancer (BC) patients [2], and subsequent research linked HER2 to poor prognoses in other malignancies, including gastric, colorectal, ovarian, and pancreatic cancers [3, 4]. This evidence concerns the gene ERBB2 and breast cancer.